联系方式：400-650-8506
CNEN
产品名称 XL 413 hydrochloride - BMS 863233 hydrochloride
产品货号 Axon 2268 CAS [1169562-71-3] MF C14H12ClN3O2.HClMW 326.18 Purity: 99% Soluble in water and DMSO Description Potent, selective and orally bioavailable CDC7 inhibitor (IC50 value of 3.4 nM) that shows >60-fold selectivity against CK2, >10-fold selectivity against PIM1, and >300-fold selectivity against a panel of over 100 protein kinases. XL 413 induces tumor cell apoptosis and inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells.Further development of XL 413 was terminated due to an unfavorable pharmacological profile observed in phase 1 clinical evaluation. References Certificates Categories Extra info R. Swords et al. Cdc7 kinase - a new target for drug development. Eur. J. Cancer. 2010, 46, 33-40.   E.S. Koltun et al. Discovery of XL413, a potent and selective CDC7 inhibitor. Bioorg. Med. Chem. Lett. 2012, 22, 3727-3371. Certificate of Analysis Material Safety Data Sheet Cell Cycle Regulation Cell Signaling & Oncology DNA-damage Response EC 2.7.11.1 CDC7 Potent, selective and orally bioavailable CDC7 inhibitor Chemical name (S)-8-Chloro-2-(pyrrolidin-2-yl)benzofuro[3,2-d]pyrimidin-4(3H)-one hydrochloride Parent CAS No. [1169558-38-6] Order Size Unit Price Stock 5 mg €120.00 In Stock
产品价格 现货询价，电话：010-67529703
产品规格
产品品牌 axonmedchem
产品概述
产品详情

XL 413 hydrochloride - BMS 863233 hydrochloride

Based on 8 reference(s) in Google Scholar 9 10 8

Axon 2268

CAS [1169562-71-3]

MF C14H12ClN3O2.HCl
MW 326.18

  • Purity: 99%
  • Soluble in water and DMSO

XL 413 hydrochloride

Description

Potent, selective and orally bioavailable CDC7 inhibitor (IC50 value of 3.4 nM) that shows >60-fold selectivity against CK2, >10-fold selectivity against PIM1, and >300-fold selectivity against a panel of over 100 protein kinases. XL 413 induces tumor cell apoptosis and inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells.Further development of XL 413 was terminated due to an unfavorable pharmacological profile observed in phase 1 clinical evaluation.
产品资料